Press Releases & Announcements

ACTG NETWORK SOLICITS FOR MEMBERSHIP TO ITS SCIENCE COMMITTEES

Aug 25, 2021

SMALL CLINICAL TRIALS ADVANCING HIV REMISSION AND CURE - DUE SEPTEMBER 1, 2021

Aug 13, 2021

ACTG LAUNCHES STUDY EVALUATING THE EFFECTS OF AN ARV CHANGE AMONG PEOPLE LIVING WITH HIV WHO EXPERIENCE EXCESSIVE WEIGHT GAIN

Jul 29, 2021

SOLICITATION FOR ACTG SCIENCE COMMITTEE LEADERSHIP POSITIONS

Jul 27, 2021

ACTG ANNOUNCES PUBLICATION OF REPRIEVE SUB-STUDY IN JAMA NETWORK OPEN, PROVIDING INSIGHTS INTO CARDIOVASCULAR DISEASE RISK AMONG PEOPLE LIVING WITH HIV

Jun 30, 2021

ACTG ANNOUNCES CAMOSTAT WILL NOT ADVANCE TO PHASE 3 IN OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 30, 2021

ACTG LAUNCHES PHASE 1 COMBINATION HIV CURE STUDY

Jun 10, 2021

ACTG ANNOUNCES THE ADDITION OF TWO MONOCLONAL ANTIBODIES TO ACTIV-2 OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 09, 2021

ACTG HONORS THE 40TH ANNIVERSARY OF HIV/AIDS

Jun 07, 2021

STUDY A5349 PUBLISHED IN NEJM

Jun 07, 2021

CENTRAL MONITORING IN A RANDOMIZED, OPEN-LABEL, CONTROLLED PHASE 3 CLINICAL TRIAL FOR A TREATMENT-SHORTENING REGIMEN FOR PULMONARY TUBERCULOSIS

May 01, 2021

ACTG LEADERSHIP STATEMENT ON DEREK CHAUVIN VERDICT

Apr 22, 2021